← Back to Analyst Consensus 
APGE Hold
Apogee Therapeutics, Inc.
Current Price —
Implied Upside —
Analysts 21
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Next Earnings
Nov 9, 2026 (14 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Aug 13, 2026 | Truist Securities | maintain | Hold → Hold | — | 54% |
| Aug 12, 2026 | BTIG | downgrade | Buy → Neutral | — | 52% |
| Jun 24, 2026 | Stifel | downgrade | Buy → Hold | — | 53% |
| Jun 24, 2026 | TD Cowen | downgrade | Buy → Hold | — | 54% |
| Jun 24, 2026 | Guggenheim | downgrade | Buy → Neutral | — | 52% |
| Jun 24, 2026 | Mizuho | downgrade | Outperform → Neutral | — | 52% |
| Jun 23, 2026 | Deutsche Bank | downgrade | Buy → Hold | — | 57% |
| Jun 23, 2026 | Citigroup | downgrade | Buy → Neutral | — | 54% |
| Jun 23, 2026 | RBC Capital | maintain | Sector Perform → Sector Perform | — | 55% |
| Jun 23, 2026 | UBS | downgrade | Buy → Neutral | — | 54% |
| Jun 23, 2026 | Wedbush | downgrade | Outperform → Neutral | — | 58% |
| Jun 22, 2026 | Canaccord Genuity | downgrade | Buy → Hold | — | 48% |
| Jun 8, 2026 | RBC Capital | maintain | Sector Perform → Sector Perform | — | 55% |
| May 27, 2026 | Truist Securities | maintain | Hold → Hold | — | 54% |
| May 27, 2026 | BTIG | reiterate | Buy → Buy | — | 52% |
| May 27, 2026 | Wedbush | maintain | Outperform → Outperform | — | 58% |
| May 1, 2026 | Rothschild & Co | initiate | — → Buy | — | 56% |
| Mar 30, 2026 | Mizuho | maintain | Outperform → Outperform | — | 52% |
| Mar 24, 2026 | Citigroup | maintain | Buy → Buy | — | 54% |
| Mar 24, 2026 | Canaccord Genuity | maintain | Buy → Buy | — | 48% |
| Mar 24, 2026 | Guggenheim | maintain | Buy → Buy | — | 52% |
| Mar 23, 2026 | BTIG | reiterate | Buy → Buy | — | 52% |
| Mar 18, 2026 | Truist Securities | initiate | — → Hold | — | 54% |
| Mar 16, 2026 | BTIG | reiterate | Buy → Buy | — | 52% |
| Mar 3, 2026 | RBC Capital | maintain | Sector Perform → Sector Perform | — | 55% |
| Mar 3, 2026 | Wedbush | maintain | Outperform → Outperform | — | 58% |
| Jan 22, 2026 | RBC Capital | downgrade | Outperform → Sector Perform | $83 | 55% |
| Jan 7, 2026 | Wolfe Research | initiate | — → Peer Perform | $0 | 53% |
| Jan 6, 2026 | BTIG | maintain | Buy → Buy | $137 | 52% |
| Jan 5, 2026 | BTIG | maintain | Buy → Buy | $128 | 52% |
| Dec 17, 2025 | Stephens & Co. | initiate | — → Overweight | $95 | 54% |
| Dec 10, 2025 | Deutsche Bank | initiate | — → Buy | $103 | 57% |
| Nov 3, 2025 | Craig-Hallum | initiate | — → Buy | $109 | 54% |
| Nov 3, 2025 | RBC Capital | maintain | Outperform → Outperform | $70 | 55% |
| Oct 21, 2025 | Mizuho | initiate | — → Outperform | $105 | 52% |
| Oct 9, 2025 | BTIG | reiterate | Buy → Buy | $115 | 52% |
| Sep 25, 2025 | RBC Capital | initiate | — → Outperform | $60 | 55% |
| Aug 28, 2025 | B of A Securities | maintain | Buy → Buy | $87 | 53% |
| Jul 2, 2025 | Guggenheim | reiterate | Buy → Buy | $116 | 52% |
| Mar 13, 2025 | Citigroup | initiate | — → Buy | $95 | 54% |
| Feb 10, 2025 | Guggenheim | reiterate | Buy → Buy | $0 | 52% |
| Dec 12, 2024 | Guggenheim | reiterate | Buy → Buy | $0 | 52% |
| Dec 3, 2024 | Guggenheim | reiterate | Buy → Buy | $110 | 52% |
| Dec 2, 2024 | Wedbush | maintain | Outperform → Outperform | $90 | 58% |
| Nov 27, 2024 | Guggenheim | maintain | Buy → Buy | $110 | 52% |
| Nov 25, 2024 | Canaccord Genuity | initiate | — → Buy | $89 | 48% |
| Oct 25, 2024 | Wedbush | reiterate | Outperform → Outperform | $87 | 58% |
| May 10, 2024 | B of A Securities | initiate | — → Buy | $80 | 53% |
| Mar 6, 2024 | Jefferies | maintain | Buy → Buy | $75 | 52% |
| Mar 5, 2024 | Stifel | maintain | Buy → Buy | $95 | 53% |
Price Target Trend
Jul 7, 2026 Latest: $134.62 Oct 24, 2026
EPS Estimates
0y $-4.86
Lo: $-4.93 Hi: $-4.79
2 analysts ▲2
0q $-1.25
Lo: $-1.27 Hi: $-1.23
2 analysts ▲2
+1y $-5.20
Lo: $-5.87 Hi: $-4.36
6 analysts ▲1
+1q $-1.37
Lo: $-1.40 Hi: $-1.34
2 analysts ▲2
Cross-Platform Signals
No cross-platform signals in the last 90 days